Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023
Transplant International · 22.08.2025 · 38
DOI: 10.3389/ti.2025.14195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, online erschienen am 22.08.2025. Verfasst von Luca Toti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Sciences, University of Rome "Tor Vergata", Rome, Italy. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Organ Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cytomegalovirus (CMV) infection poses significant challenges in solid organ transplant (SOT) recipients, impacting graft outcomes, morbidity, and in some cases survival. The ESOT CMV Workshop 2023 convened European experts to discuss current practices and advances in the management of CMV with the aim of improving the quality of life of transplant recipients. Discussions covered crucial areas such as preventive strategies, diagnostic challenges, therapeutic approaches, and the role of cell-mediated immunity (CMI) monitoring. Despite advances, ambiguity persists in optimal CMV management across European transplant centers. Preventive strategies, including universal prophylaxis and pre-emptive therapy, are effective but consensus is lacking with respect to the preferred approach. Diagnostic challenges such as standardization of viral load thresholds and detection of end-organ disease complicate timely intervention. While newer therapies like maribavir hold promise for treating complicated CMV infections, sustaining viral clearance remains a challenge. Integrating CMI monitoring into CMV management could personalize treatment decisions but has limitations in in terms of predictive value and accessibility. Further research is needed to fill these gaps and optimize CMV management. The collaborative efforts, led by the European Society for Organ Transplantation (ESOT), aim to standardize and improve CMV care, ensuring better outcomes for SOT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Sciences, University of Rome "Tor Vergata", Rome, Italy.
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, INFINITY-Inserm U1291-CNRS U5051, University Paul Sabatier, Toulouse, France.
- Department of Virology and National Reference Center for Herpesviruses, Limoges University Hospital, UMR Inserm 1092, University of Limoges, Limoges, France.
- University Hospital Federation SUPORT, Limoges, France.
- Infectious Diseases Service and Transplantation Center, University Hospital and University of Lausanne, Lausanne, Switzerland.
- Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia.
Zitieren
APA
Toti, L., Kamar, N., Alain, S., Manuel, O., Basic-Jukic, N., Grossi, P. A., Kaminski, H., Solidoro, P., & Potena, L. (2025). Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023. Transplant International, 38. https://doi.org/10.3389/ti.2025.14195
Vancouver
Toti L, Kamar N, Alain S, Manuel O, Basic-Jukic N, Grossi PA, et al. Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023. Transplant International. 2025;38. doi:10.3389/ti.2025.14195
BibTeX
@article{Toti2025,
author = {Toti, Luca and Kamar, Nassim and Alain, Sophie and Manuel, Oriol and Basic-Jukic, Nikolina and Grossi, Paolo Antonio and Kaminski, Hannah and Solidoro, Paolo and Potena, Luciano},
title = {Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023},
journal = {Transplant International},
year = {2025},
volume = {38},
doi = {10.3389/ti.2025.14195}
}
EUVIMED